Tech Company Financing Transactions
Seamless Therapeutics Funding Round
Forbion Capital Partners, Wellington Partners and BMBF GO-Bio participated in a $12.5 million funding round for Seamless Therapeutics. The funding round was announced on 3/16/2023.
Transaction Overview
Company Name
Announced On
3/16/2023
Transaction Type
Venture Equity
Amount
$12,500,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to further advance its proprietary technology platform to build a pipeline of therapeutic candidates towards first-in-human readiness as well as to expand the presence in the EU & US.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Tatzberg 47/49
Dresden, 01307
DE
Dresden, 01307
DE
Phone
Website
Email Address
Overview
Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Our technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes. We are applying our proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Anne Heninger
Chief Financial Officer
Anne Burger
Chief Scientific Officer
Felix Lansing
VP - Bus. Development
Arturo Urrios
Browse more venture capital transactions:
Prev: 3/16/2023: TeleportDAO venture capital transaction
Next: 3/16/2023: Andes venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs